Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (SNWV) pioneers noninvasive regenerative solutions through its proprietary PACE™ technology, advancing wound care and tissue repair innovations. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in developing FDA-cleared medical devices.
Access authoritative information about SNWV's technological advancements, including clinical trial outcomes, regulatory milestones, and strategic partnerships. Our curated collection features:
• FDA clearance announcements for new medical devices
• Clinical study results demonstrating treatment efficacy
• Financial performance updates and corporate developments
• Technology licensing agreements and partnership news
Bookmark this page for reliable updates on Sanuwave Health's progress in revolutionizing noninvasive therapies for wound management, orthopedic conditions, and aesthetic procedures. Verify all investment decisions against official SEC filings and consult medical professionals for clinical guidance.
SANUWAVE Health, Inc. (PINK: SNWV) announced its shares will cease trading on the OTC Market Pink due to untimely financial report filings with the SEC, moving to the expert market instead. Despite this, the company reported strong operational performance with record unit shipments in August and a robust pipeline. Management expects to achieve break-even sales and outlines plans for cost savings through manufacturing relocations. Updates on financial reports and a conference call to discuss results are anticipated.
SANUWAVE Health (OTCQB: SNWV) has announced a collaboration with NASA to tackle bacterial biofilms in the Water Recovery System (WRS) essential for long-duration space missions. Utilizing their proprietary shockwave technology, SANUWAVE aims to prevent biofilm formation that poses risks to water systems used in human habitats on the Moon and Mars. This partnership is significant for ensuring clean water for future lunar and Martian missions, and SANUWAVE's innovative solutions may extend to various commercial applications in water cleaning and disinfection.
SANUWAVE Health (OTCQB:SNWV) has announced updated dial-in instructions for its conference call on July 15, 2021, at 4:30 PM ET. The call will cover recent business activities, SEC filing updates, and strategic initiatives. Participants can join by calling Toll-Free: 844-407-9500 or International: 862-298-0850. A replay will be available through July 22, 2021, using Toll-Free: 877-481-4010 and International: 919-882-2331 with the passcode 42095. SANUWAVE focuses on advanced wound care and regenerative medicine.
SANUWAVE Health (OTCQB:SNWV) will host a conference call on July 15, 2021, at 4:30pm ET, to discuss recent business activities, SEC filings, and strategic initiatives. All interested parties can access the call by dialing 678-578-0113 in the U.S. SANUWAVE focuses on developing next-generation wound care products utilizing patented energy transfer technologies aimed at enhancing wound healing and tissue regeneration. Further information about SANUWAVE can be found at www.SANUWAVE.com.
SANUWAVE Health (OTCQB:SNWV) announced on July 2, 2021, that its shares will transition to pink sheets due to late financial filings with the SEC. The CEO, Kevin Richardson, attributed the delays to accounting system issues, asserting they are being resolved and that current filings are forthcoming. The company remains optimistic about its operations, citing a distribution agreement in Latin America and strong clinical study results. Their UltraMIST systems are seeing record sales, and the recent relaunch of the ENERGY FIRST platform is gaining traction, suggesting potential growth ahead.
SANUWAVE Health, Inc. (OTCQB:SNWV) recently reported promising results from a clinical case series on its dermaPACE System, an FDA-cleared treatment for diabetic foot ulcers. The study, published in the American Journal of Nursing Science, showed a 25% increase in tissue oxygen saturation and a 46.7% full wound closure rate among patients over four weeks. This signifies the system's effectiveness in enhancing wound healing and could transform management strategies for chronic wounds in diabetic patients, impacting around 30.3 million Americans.
SANUWAVE Health, Inc. (OTCQB:SNWV) announces its participation in the LD Micro Invitational XI conference, scheduled for June 8-10, 2021. CEO Kevin Richardson will present on June 10, 2021, at 4:30 p.m. EDT. The presentation will cover SANUWAVE's innovative wound care solutions that leverage patented biological response-activating technologies. Interested parties can access a live audio webcast at this link. The company focuses on non-invasive medical systems for healing and regeneration in various medical fields.
SANUWAVE Health, Inc. (OTCQB:SNWV) has announced a distribution agreement with Grupo Suprimed to market and sell its dermaPACE System in Brazil's private healthcare sector. This agreement aims to strengthen SANUWAVE's presence in Brazil, the largest healthcare market in Latin America, which has a vast network of hospitals and healthcare professionals. SANUWAVE’s CEO highlighted the potential for improving healthcare quality and lowering costs through this partnership, while Grupo Suprimed is recognized as a significant distributor of medical products in the region.
SANUWAVE Health (OTCQB:SNWV) has engaged MZ Group to enhance its investor relations and financial communications strategy. This partnership aims to boost the company's visibility in the investment community, particularly for its Energy First wound care product line. The U.S. diabetic foot ulcer market, valued at $15 billion, underscores the growth potential. The firm will assist in roadshows and promote SANUWAVE's differentiating technologies, including non-contact ultrasound devices and biologics. Leadership anticipates significant revenue growth due to positive reimbursement dynamics.
SANUWAVE Health (OTCQB:SNWV) will present at the Q2 Virtual Investor Summit on May 18, 2021, starting at 11:45 a.m. ET. Kevin Richardson, the company's CEO, will engage in one-on-one meetings with investors during this event. Registration is required for participation. SANUWAVE specializes in the development of advanced wound care medical systems that facilitate the repair and regeneration of skin and vascular structures. The company’s focus is on innovative solutions using non-invasive technologies for various medical applications.
